Elpiscience

Executive Summary

Elpiscience is a Shanghai-based biopharmaceutical company specializing in novel immuno-oncology therapies, with a distinct focus on macrophage-targeting biologics. Leveraging its proprietary drug discovery platform, the company develops bispecific antibodies and other biologic modalities designed to modulate the tumor microenvironment. Since its founding in 2018, Elpiscience has built a pipeline of early-stage candidates addressing key mechanisms in cancer immunotherapy. As a private company with 100-200 employees, it operates in the competitive oncology space, aiming to differentiate through macrophage biology. The company's stage (Phase 1) indicates initial clinical data may emerge in the near term, but limited public information constrains near-term valuation visibility.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 data readout for lead macrophage-targeting bispecific antibody30% success
• Q4 2027Initiation of Phase 2 trial for lead candidate25% success
• Q3 2026Strategic partnership or licensing deal for pipeline asset20% success